인쇄하기
취소

Boehringer’s approved ‘Jardiance Duo’ fuels competition among SGLT-2 complexes

Published: 2016-01-25 14:56:29
Updated: 2016-01-25 14:56:29

In the SGLT-2-inhibitor antidiabetic treatment market led by AstraZeneca’s ‘Forxiga(dapagliflozin)’ by itself, competition is expected among complexes.

According to the industry concerned on the 22nd, ‘Jardiance Duo Tab,’ a Boehringer Ingelheim’s SGLT-2 inhibitor, is looking forward to its domestic launch as recently approved by the Ministry of Health and Welfare.

Jardiance Duo is a complex o...

Fees

- Email service daily and homepage access.
  1. $300 per month.
  2. 5 Email holders per each company.
  3. Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.